5.3 Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules
Key Takeaways
- Community-Acquired Pneumonia (CAP) is diagnosed by clinical signs of lower respiratory infection combined with a demonstrable new pulmonary infiltrate on chest radiography.
- Site-of-care determination in CAP relies on the CURB-65 score: Confusion, Urea > 19 mg/dL, Respiratory rate ≥ 30, Blood pressure < 90/60 mmHg, Age ≥ 65 (Score 0–1 = outpatient; Score 2 = inpatient observation/admission; Score ≥ 3 = ICU/urgent inpatient).
- Outpatient empiric CAP pharmacotherapy requires stratification: Amoxicillin 1 g TID or Doxycycline 100 mg BID for healthy adults without comorbidities; Combination therapy (Augmentin or Cephalosporin PLUS Macrolide or Doxycycline) OR Respiratory Fluoroquinolone monotherapy for adults with chronic comorbidities.
- Acute bronchitis is viral in >90% of cases; routine antibiotic prescription is strongly contraindicated regardless of sputum purulence.
- Light's criteria differentiate exudative from transudative pleural effusions; an exudate meets at least ONE of: Pleural/Serum Protein > 0.5, Pleural/Serum LDH > 0.6, or Pleural LDH > 2/3 upper limit of normal serum LDH.
Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules
Lower respiratory disorders represent a substantial proportion of acute primary care encounters and diagnostic dilemmas in adult and geriatric medicine. Accurate clinical evaluation requires distinguishing self-limiting viral bronchitis from life-threatening bacterial Community-Acquired Pneumonia (CAP), calculating objective risk stratification scores, applying evidence-based antibiotic stewardship, analyzing pleural fluid dynamics via Light's criteria, and managing incidental solitary pulmonary nodules.
For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP), board certification demands mastery of the ATS/IDSA pneumonia guidelines, CURB-65 risk scores, pleural effusion differentiation, and Fleischner Society pulmonary nodule surveillance protocols.
1. Community-Acquired Pneumonia (CAP): Microbiology & Clinical Manifestations
Community-Acquired Pneumonia (CAP) is defined as an acute infection of the pulmonary parenchyma acquired outside of a hospital or healthcare facility. Definitive diagnosis requires the presence of an acute pulmonary infiltrate on chest radiography (CXR) or CT scan in a patient with a compatible clinical syndrome (fever, cough, dyspnea, pleuritic chest pain, leukocytosis, crackles).
+---------------------------------------------------------------------------------------------------+
| CAP MICROBIOLOGICAL TAXONOMY |
| |
| 1. TYPICAL BACTERIAL PATHOGENS |
| - Streptococcus pneumoniae (Pneumococcus): #1 overall cause of CAP across all age groups. |
| Classic presentation: Sudden rigor/chills, high fever, "rust-colored" sputum, dense lobar |
| consolidation, positive urinary antigen test. |
| - Haemophilus influenzae: Common in smokers, COPD, cystic fibrosis. |
| - Moraxella catarrhalis: Common in elderly patients with preexisting lung disease. |
| - Staphylococcus aureus (MSSA / MRSA): Post-influenza / viral pneumonia complication; causes |
| severe necrotizing pneumonia, multiple cavitary lesions, pneumatoceles, and high mortality. |
| - Klebsiella pneumoniae: Alcohol use disorder, diabetic patients, aspiration risk; classic |
| "currant-jelly" thick blood-tinged sputum, upper lobe cavitary necrosis. |
| - Pseudomonas aeruginosa: Severe bronchiectasis, cystic fibrosis, advanced structural COPD. |
| |
| 2. ATYPICAL PATHOGENS |
| - Mycoplasma pneumoniae: #1 in young adults/college students ("Walking Pneumonia"); gradual |
| onset, non-productive dry cough, bullous myringitis, cold agglutinin-mediated hemolytic anemia.|
| - Chlamydia pneumoniae: Pharyngitis and hoarseness followed by persistent subacute cough. |
| - Legionella pneumophila: Exposure to aerosolized water sources (cooling towers, hotel plumbing, |
| cruises). High fever, bradycardia relative to fever (Faget's sign), severe GI symptoms |
| (diarrhea, nausea), profound Hyponatremia (<130 mEq/L), elevated AST/ALT. Urinary antigen test.|
| |
| 3. ASPIRATION PNEUMONIA |
| - Polymicrobial (Oral anaerobes: Peptostreptococcus, Fusobacterium, Prevotella + Streptococci). |
| - Risk Factors: Stroke, dysphagia, alcoholism, altered consciousness, seizure disorder, dementia|
| - Anatomical Location: Superior segment of Right Lower Lobe (supine) or RLL base (upright). |
+---------------------------------------------------------------------------------------------------+
2. Risk Stratification & Site-of-Care Determination: CURB-65 & PSI
Determining whether a patient with CAP can be safely managed in the outpatient setting or requires inpatient hospitalization or ICU admission is the most crucial clinical safety decision made by the AGPCNP.
+---------------------------------------------------------------------------------------------------+
| CURB-65 RISK STRATIFICATION SCORE |
| |
| CRITERION POINTS ASSIGNED |
| --------------------------------------------------------------------------------------------- |
| C - CONFUSION (New mental confusion; AMTS <= 8 or disorientation to person/place/time) 1 |
| U - UREA (Blood Urea Nitrogen [BUN] > 19 mg/dL or > 7 mmol/L) 1 |
| R - RESPIRATORY RATE (>= 30 breaths per minute) 1 |
| B - BLOOD PRESSURE (Systolic BP < 90 mmHg OR Diastolic BP <= 60 mmHg) 1 |
| 65- AGE >= 65 YEARS 1 |
| --------------------------------------------------------------------------------------------- |
| TOTAL POSSIBLE SCORE: 5 |
+---------------------------------------------------------------------------------------------------+
+---------------------------------------------------------------------------------------------------+
| CURB-65 CLINICAL DISPOSITION ALGORITHM |
| |
| SCORE 0 to 1 ---> LOW RISK (30-day mortality < 1.5%) |
| Disposition: Outpatient treatment is safe and recommended. |
| |
| SCORE 2 ---> MODERATE RISK (30-day mortality ~9.2%) |
| Disposition: Consider short inpatient hospital admission or close |
| monitored outpatient setting with 24-48 hr reassessment. |
| |
| SCORE 3 to 5 ---> HIGH RISK (30-day mortality 15% to 40%) |
| Disposition: URGENT INPATIENT HOSPITALIZATION. Score 4-5 warrants |
| direct evaluation for Intensive Care Unit (ICU) admission. |
+---------------------------------------------------------------------------------------------------+
[!NOTE] Pneumonia Severity Index (PSI / PORT Score): While CURB-65 is the preferred rapid bedside tool, the ATS/IDSA guidelines strongly endorse the Pneumonia Severity Index (PSI) as the gold-standard prediction model. Patients in PSI Risk Classes I–II (score $\le 70$) are treated as outpatients; Class III (score 71–90) can be managed in an observation unit; and Classes IV–V (score $>90$) mandate inpatient hospital admission.
3. ATS/IDSA Outpatient Pharmacotherapy Guidelines for CAP
Empiric outpatient antibiotic selection is divided strictly by the patient's underlying comorbidities and risk factors for drug-resistant pathogens:
+---------------------------------------------------------------------------------------------------+
| ATS/IDSA OUTPATIENT CAP EMPIRIC PHARMACOTHERAPY MATRIX |
| |
| [CATEGORY 1: HEALTHY OUTPATIENT ADULTS WITHOUT COMORBIDITIES] |
| - Criteria: No chronic heart, lung, liver, or renal disease; no diabetes; no alcoholism; |
| no malignancy; no asplenia; no immunosuppression; no recent antibiotic use in prior 90 days. |
| |
| * FIRST-LINE (STRONG RECOMMENDATION): |
| AMOXICILLIN 1 g orally THREE TIMES DAILY (TID) x 5-7 days. |
| |
| * SECOND-LINE / ALTERNATIVE (CONDITIONAL RECOMMENDATION): |
| DOXYCYCLINE 100 mg orally TWICE DAILY (BID) x 5-7 days. |
| |
| * MACROLIDE MONOTHERAPY (Azithromycin 500 mg day 1, then 250 mg daily; or Clarithromycin 500 mg):|
| Recommended ONLY in regions where pneumococcal macrolide resistance is documented < 25%. |
| (In the US, macrolide resistance exceeds 40-50%; MACROLIDE MONOTHERAPY IS NOT RECOMMENDED!). |
| |
| --------------------------------------------------------------------------------------------- |
| [CATEGORY 2: OUTPATIENT ADULTS WITH CHRONIC COMORBIDITIES] |
| - Criteria: Presence of COPD, DM, CHF, CKD, liver cirrhosis, alcoholism, malignancy, asplenia, |
| or systemic antibiotic therapy within the preceding 90 days. |
| |
| * OPTION A: COMBINATION THERAPY (BETA-LACTAM + MACROLIDE OR DOXYCYCLINE): |
| - Beta-Lactam Backbone (Choose One): |
| 1. Amoxicillin-Clavulanate (Augmentin 875/125 mg PO BID or 2000/125 mg PO BID), OR |
| 2. Cefuroxime (500 mg PO BID) or Cefpodoxime (200 mg PO BID) |
| - PLUS (Choose One for Atypical Coverage): |
| 1. Azithromycin (500 mg day 1, then 250 mg daily), OR |
| 2. Doxycycline (100 mg PO BID) |
| |
| * OPTION B: RESPIRATORY FLUOROQUINOLONE MONOTHERAPY: |
| - LEVOFLOXACIN 750 mg orally ONCE DAILY x 5 days, OR |
| - MOXIFLOXACIN 400 mg orally ONCE DAILY x 5 days. |
| (Reserve for patients with severe beta-lactam anaphylaxis due to FDA Black Box Warnings). |
+---------------------------------------------------------------------------------------------------+
Clinical Antibiotic Rules & Duration:
- Duration of Therapy: Minimum of 5 full days. The patient must be afebrile for $\ge 48\text{--}72\text{ hours}$ and achieve clinical stability (HR $<100$, RR $<24$, $\text{SBP} \ge 90\text{ mmHg}$, $\text{SpO}_2 \ge 90%$) before stopping antibiotics.
- Follow-up Chest X-ray: Routine repeat CXR is not recommended in young, improving patients. However, in adults aged $>50$ years or smokers, obtain a follow-up CXR in 6 to 12 weeks to confirm complete radiographic resolution and exclude an underlying endobronchial malignancy.
4. Acute Bronchitis vs. CAP & Antibiotic Stewardship
Acute bronchitis is a self-limiting inflammation of the large conducting airways (trachea and bronchi) presenting with a cough lasting 1 to 3 weeks (average 10–21 days).
+---------------------------------------------------------------------------------------------------+
| ACUTE BRONCHITIS VS. PNEUMONIA DIFFERENTIATION |
| |
| CLINICAL FEATURE ACUTE BRONCHITIS PNEUMONIA (CAP) |
| --------------------------------------------------------------------------------------------- |
| PRIMARY ETIOLOGY VIRAL (> 90-95% of cases) BACTERIAL (S. pneumo, atypicals) |
| CHEST RADIOGRAPHY NORMAL (No infiltrates) NEW PULMONARY INFILTRATE / CONSOL. |
| SYSTEMIC VITAL SIGNS Normal (HR < 100, RR < 20, Abnormal (Tachypnea, Tachycardia, |
| Afebrile or low-grade) Fever > 38.0 C / 100.4 F) |
| PULMONARY EXAM Clear or scattered wheezes / Localized crackles, egophony, |
| rhonchi that clear with cough whispered pectoriloquy, dullness |
| ANTIBIOTIC INDICATION STRICTLY NOT RECOMMENDED MANDATORY EMPIRIC ANTIBIOTICS |
+---------------------------------------------------------------------------------------------------+
[!WARNING] The Sputum Purulence Myth: Sputum color (green or yellow vs. clear) is caused by the release of myeloperoxidase enzymes from cellular neutrophils entering the tracheobronchial tree. Sputum purulence correlates with local airway inflammation, NOT bacterial infection. In the absence of abnormal vital signs or focal lung consolidation, green sputum in acute bronchitis is NOT an indication for antibiotic therapy.
Evidence-Based Management of Acute Bronchitis:
- Reassurance and Patient Education: Emphasize that acute bronchitis is viral, self-limiting, and cough typically persists for 2 to 3 weeks.
- Symptomatic Pharmacotherapy: OTC dextromethorphan, guaifenesin, warm liquids, honey (in adults), and inhaled short-acting beta-agonists (albuterol) only if active wheezing is present on examination.
5. Pleural Effusions & Light's Diagnostic Criteria
A Pleural Effusion is an abnormal accumulation of fluid in the pleural space between the parietal and visceral pleura.
+---------------------------------------------------------------------------------------------------+
| PLEURAL EFFUSION PATHOPHYSIOLOGY |
| |
| 1. TRANSUDATIVE EFFUSIONS ("Clean Water / Systemic Imbalance") |
| - Pathophysiology: Altered systemic hydrostatic or oncotic pressures; pleural membranes INTACT. |
| - Etiologies: Congestive Heart Failure (#1 overall transudate), Hepatic Cirrhosis with |
| hydrothorax, Nephrotic Syndrome, Severe Hypoalbuminemia, Peritoneal Dialysis. |
| |
| 2. EXUDATIVE EFFUSIONS ("Protein-Rich / Local Inflammation") |
| - Pathophysiology: Local inflammation or injury causing increased capillary permeability or |
| impaired lymphatic drainage; pleural membranes INFLAMED/DAMAGED. |
| - Etiologies: Parapneumonic Effusion / Empyema (#1 exudate), Malignancy (lung, breast, lymphoma),|
| Pulmonary Embolism, Tuberculosis, Pancreatitis, Rheumatoid Arthritis / Lupus, Trauma. |
+---------------------------------------------------------------------------------------------------+
Light's Diagnostic Criteria for Exudative Effusions
Perform a diagnostic Thoracentesis whenever an unexplained pleural effusion $>1\text{ cm}$ on decubitus film is detected. Send pleural fluid for Protein, LDH, Glucose, pH, Cell count with differential, Gram stain, and Cytology.
+---------------------------------------------------------------------------------------------------+
| LIGHT'S CRITERIA (RULE FOR EXUDATES) |
| |
| A pleural effusion is classified as an EXUDATE if IT MEETS AT LEAST ONE of the following: |
| |
| 1. Pleural Fluid Protein / Serum Protein Ratio > 0.5 |
| 2. Pleural Fluid LDH / Serum LDH Ratio > 0.6 |
| 3. Pleural Fluid LDH > 2/3 the upper limit of normal for serum LDH |
| (i.e., > 0.67 x Upper Limit of Normal) |
| |
| * TRANSUDATE: Meets NONE of the 3 criteria (all values below thresholds). |
+---------------------------------------------------------------------------------------------------+
Parapneumonic Effusions & Empyema Decision Matrix
| Classification | Pleural Fluid Biochemistry & Microbiology | Clinical Significance & Management |
|---|---|---|
| Uncomplicated Parapneumonic | $\text{pH} > 7.20$, Glucose $>60\text{ mg/dL}$, $\text{LDH} < 1,000\text{ U/L}$, negative Gram stain and culture. | Resolves with systemic IV/oral antibiotic therapy for pneumonia alone; no chest tube required. |
| Complicated Parapneumonic | $\text{pH} < 7.20$, Glucose $<40\text{ mg/dL}$, $\text{LDH} > 1,000\text{ U/L}$, Gram stain or culture may be positive. | High risk of loculation/fibrin scarring; MANDATORY URGENT TUBE THORACOSTOMY (CHEST TUBE DRAINAGE) + antibiotics. |
| Empyema | Frank, grossly purulent fluid (pus), positive Gram stain or culture, $\text{pH} < 7.20$, Glucose $<40\text{ mg/dL}$. | MANDATORY CHEST TUBE DRAINAGE; intrapleural fibrinolytics (tPA + DNase) or surgical decortication via VATS. |
6. Solitary Pulmonary Nodules (SPN) & Fleischner Society Guidelines
A Solitary Pulmonary Nodule (SPN) is defined as a single, discrete, well-circumscribed radiographic opacity $\le 30\text{ mm}$ (3 cm) in diameter, surrounded entirely by normal aerated lung parenchyma, without associated atelectasis, lymphadenopathy, or pleural effusion. (Lesions $>30\text{ mm}$ are termed pulmonary masses and are presumed malignant until proven otherwise).
+---------------------------------------------------------------------------------------------------+
| SOLITARY PULMONARY NODULE RISK STRATIFICATION |
| |
| FEATURE BENIGN CHARACTERISTICS MALIGNANT CHARACTERISTICS |
| --------------------------------------------------------------------------------------------- |
| PATIENT AGE < 35 years > 50 years |
| SMOKING HISTORY Non-smoker Heavy active/former smoker |
| SIZE < 6 mm (Risk < 1%) > 8 mm; especially > 20 mm (> 50%) |
| MARGINS Smooth, sharp, well-defined Spiculated, corona radiata, lobated|
| CALCIFICATION PATTERN Dense central, diffuse, laminated, Eccentric, stippled, or punctate |
| or "Popcorn" (Hamartoma hallmark) |
| GROWTH RATE Stable on prior imaging for >= 2 years Rapid volume doubling time (30-400d)|
+---------------------------------------------------------------------------------------------------+
Fleischner Society 2017 Management Guidelines for Incidental Solid Nodules (Age ≥35)
+---------------------------------------------------------------------------------------------------+
| FLEISCHNER SOCIETY 2017 SOLID NODULE ALGORITHM |
| |
| NODULE SIZE LOW-RISK PATIENT HIGH-RISK PATIENT |
| --------------------------------------------------------------------------------------------- |
| < 6 mm No routine follow-up required Optional repeat CT at 12 months |
| (Single solid) |
| |
| 6 mm to 8 mm Repeat CT at 6 to 12 months; Repeat CT at 6 to 12 months; |
| (Single solid) then consider repeat CT at 18-24 mo then repeat CT at 18 to 24 months |
| |
| > 8 mm Consider CT at 3 months, PET-CT, Consider CT at 3 months, PET-CT, |
| (Single solid) tissue biopsy, or surgical resection tissue biopsy, or surgical resection|
+---------------------------------------------------------------------------------------------------+
7. Board-Yield Summary & Diagnostic Pearls
+---------------------------------------------------------------------------------------------------+
| ANCC AGPCNP CLINICAL EXAM PEARLS |
| |
| - In suspected CAP, the presence of diarrhea, severe hyponatremia (<130 mEq/L), and elevated |
| hepatic transaminases in a patient exposed to a hotel or cooling tower is LEGIONELLA. Order |
| a Urine Legionella Antigen test and treat with Levofloxacin or Azithromycin! |
| |
| - Never prescribe standalone macrolide monotherapy for CAP in a patient with diabetes, COPD, or|
| heart failure. Comorbid patients require combination Augmentin + Macrolide/Doxycycline or a |
| respiratory fluoroquinolone. |
| |
| - Acute bronchitis does NOT require antibiotics. Green sputum reflects neutrophil myeloperoxidase|
| and is NOT an indicator of bacterial infection. |
| |
| - Parapneumonic pleural fluid with pH < 7.20, Glucose < 40 mg/dL, or gross pus requires urgent |
| CHEST TUBE INSERTION. Antibiotics alone will fail and lead to trapped lung fibrothorax. |
| |
| - A pulmonary nodule with "popcorn calcification" is a benign pulmonary hamartoma; a nodule |
| with stability documented on chest CT for >= 2 years requires no further workup. |
+---------------------------------------------------------------------------------------------------+
A 72-year-old male with a history of type 2 diabetes mellitus and hypertension presents to the primary care clinic with a 3-day history of shaking chills, productive cough with blood-tinged sputum, and right-sided pleuritic chest pain. Vital signs: BP 86/54 mmHg, HR 108 bpm, RR 32 bpm, Temp 38.9°C (102.0°F), SpO2 89% on room air. Physical exam reveals right lower lobe dullness to percussion and bronchial breath sounds with egophony. Laboratory evaluation reveals a BUN of 28 mg/dL and serum creatinine of 1.4 mg/dL. Mental status exam shows he is fully alert and oriented. Chest X-ray demonstrates dense right lower lobe lobar consolidation. What is his CURB-65 score and what is the most appropriate clinical disposition?
A 58-year-old female with a history of severe rheumatoid arthritis and recurrent right-sided pneumonia undergoes a diagnostic thoracentesis for an expanding right pleural effusion. Laboratory analysis of the pleural fluid and simultaneous serum chemistry reveals: Pleural Fluid Total Protein: 4.2 g/dL (Serum Total Protein: 6.8 g/dL); Pleural Fluid LDH: 340 U/L (Serum LDH: 400 U/L; Upper Limit of Normal Serum LDH: 200 U/L); Pleural Fluid Glucose: 28 mg/dL; Pleural Fluid pH: 7.12. Gram stain demonstrates numerous polymorphonuclear leukocytes but no visible organisms. How should the AGPCNP classify this pleural effusion, and what is the mandatory next step in clinical management?
A 64-year-old male former smoker (30 pack-year history, quit 4 years ago) presents to the clinic for follow-up of an incidental solitary pulmonary nodule discovered on an abdominal CT scan performed for diverticulitis. The report notes a single, solid, non-calcified nodule measuring 11 mm in diameter located in the right upper lobe, with irregular, spiculated margins. He is currently asymptomatic with no cough, hemoptysis, or weight loss. Comparison with a chest X-ray from 4 years ago shows no visible nodule at that location. According to the Fleischner Society guidelines and thoracic oncology standards, which of the following is the most appropriate next diagnostic step?